A large Nature Medicine study used years of routine cancer-care data to chart when patients entered and left periods of cachectic weight loss. The researchers linked those episodes with blood-test patterns, disease progression, survival and tumor mutations, creating a detailed view of a syndrome that is common but still difficult to predict.
Cancer cachexia is a metabolic syndrome marked by unintended weight loss and muscle wasting. It can interfere with treatment and daily life, but its course varies widely among patients and cancer types. Instead of treating cachexia as a single yes-or-no diagnosis, the study followed distinct weight-loss episodes over time.
Tracking more than 30,000 episodes
The team analyzed 52,236 adults treated at Memorial Sloan Kettering Cancer Center and profiled through the MSK-IMPACT tumor-sequencing program from 2010 through 2024. The dataset covered 589 cancer histologies and included about 1.74 million body mass index measurements.
Researchers defined an episode using consensus weight-loss thresholds: at least 5% over six months, or at least 2% for patients whose starting BMI was below 20. The method identified 30,938 episodes affecting 46.63% of the cohort. More than one in five affected patients experienced multiple episodes.
The episodes were not evenly distributed. Gastrointestinal cancers had some of the highest prevalence, while prostate cancer and chronic lymphocytic leukemia had lower rates. Episodes also tended to occur near documented disease progression and were associated with worse survival across nearly all of the cancer types examined.
